PCI in patients with FFR ≤ 0.80 reduced clinical events by 66% compared to medical therapy alone at 1 year.
The FAME II Trial randomized stable CAD patients with FFR ≤ 0.80 to PCI + medical therapy or medical therapy alone. Enrollment was halted early after 1,220 patients because of a significant between-group difference in the events, driven by a lower rate of urgent revascularization in the PCI group than in the medical therapy group. Continue reading “FAME II Trial”
14% reduction in overall costs at 1 year.
Economic analysis of the FAME Trial revealed that PCI guided by FFR saves costs and improves health outcomes at 1 year compared with angiography guidance. Cost savings are driven by a decrease in stent use during the initial procedure, a decrease in rehospitalization and fewer major adverse cardiac events. Continue reading “FAME Trial Economic Analysis”
28% relative reduction in clinical events at 1 year.
The FAME trial compared FFR-guided PCI decision- making (by pressure wire) versus PCI guided by angiography alone in 1,005 randomized patients with multi-vessel coronary artery disease. Routine measurement of FFR significantly reduced clinical events at 1 year. Continue reading “FAME Trial”